These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 7662995)

  • 1. Detection of minimal residual disease in acute leukemia.
    Seshadri R
    Blood; 1995 Sep; 86(6):2452. PubMed ID: 7662995
    [No Abstract]   [Full Text] [Related]  

  • 2. Detection of minimal residual disease in hematopoietic tissues.
    Sharp JG; Bishop M; Chan WC; Greiner T; Joshi SS; Kessinger A; Reed E; Sanger W; Tarantolo S; Traystman M
    Ann N Y Acad Sci; 1995 Dec; 770():242-61. PubMed ID: 8597365
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of PCR technology for detecting minimal residual disease in patients with leukemia.
    Radich JP
    Rev Immunogenet; 1999; 1(2):265-78. PubMed ID: 11253952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular evidence for minimal residual bone marrow disease in children with 'isolated' extra-medullary relapse of T-cell acute lymphoblastic leukemia.
    Neale GA; Pui CH; Mahmoud HH; Mirro J; Crist WM; Rivera GK; Goorha RM
    Leukemia; 1994 May; 8(5):768-75. PubMed ID: 8182934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histology of bone marrow in acute leukaemia.
    Dominis M; Dzebro S
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():10-1. PubMed ID: 2627593
    [No Abstract]   [Full Text] [Related]  

  • 6. Measurement of minimal residual disease in acute leukemia.
    Morley A
    Leukemia; 1996 May; 10(5):920-2. PubMed ID: 8656691
    [No Abstract]   [Full Text] [Related]  

  • 7. [Detection of minimal residual leukemia using polymerase chain reaction method].
    Naoe T
    Rinsho Byori; 1996 Jun; 44(6):535-40. PubMed ID: 8752731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved.
    Ouspenskaia MV; Johnston DA; Roberts WM; Estrov Z; Zipf TF
    Leukemia; 1995 Feb; 9(2):321-8. PubMed ID: 7869771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High sensitivity and specificity assay for detection of leukemia/lymphoma cells in human bone marrow.
    Bregni M; Siena S; Dalla-Favera R; Gianni AM
    Ann N Y Acad Sci; 1987; 511():473-82. PubMed ID: 3125782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of residual disease in acute leukemia using immunological markers.
    Ryan DH; van Dongen JJ
    Cancer Treat Res; 1988; 38():173-207. PubMed ID: 2908595
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
    Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
    N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal processing of bone marrow trephine biopsy: the Hammersmith Protocol.
    Naresh KN; Lampert I; Hasserjian R; Lykidis D; Elderfield K; Horncastle D; Smith N; Murray-Brown W; Stamp GW
    J Clin Pathol; 2006 Sep; 59(9):903-11. PubMed ID: 16935969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Methods of evaluating residual disease in bone marrow in malignant hemopathies. Prospectives].
    Hervé P; Favrot M
    Nouv Rev Fr Hematol (1978); 1987; 29(2):103-6. PubMed ID: 3302940
    [No Abstract]   [Full Text] [Related]  

  • 14. Detection and quantitation of genetically marked acute myeloid leukemia by competitive polymerase chain reaction after autologous bone marrow transplantation: a preclinical model for minimal residual disease.
    Kühr T; Bechter O; Geley S; Eisterer W; Lukas P; Url M; Dietrich H; Hilbe W; Kofler R; Thaler J
    Exp Hematol; 1999 Feb; 27(2):266-71. PubMed ID: 10029166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Minimal residual disease].
    Francia di Celle P; Foà R
    Haematologica; 1991 Jun; 76 Suppl 3():303-10. PubMed ID: 1752527
    [No Abstract]   [Full Text] [Related]  

  • 16. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia.
    Roberts WM; Estrov Z; Ouspenskaia MV; Johnston DA; McClain KL; Zipf TF
    N Engl J Med; 1997 Jan; 336(5):317-23. PubMed ID: 9011783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma.
    Puig N; Sarasquete ME; Alcoceba M; Balanzategui A; Chillón MC; Sebastián E; Marín LA; Díaz MG; San Miguel JF; Sanz RG
    Ann Hematol; 2013 Jan; 92(1):97-100. PubMed ID: 22956183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymerase chain reaction (PCR) approach for the evaluation of minimal residual disease in acute leukemia.
    Biondi A; Rambaldi A
    Stem Cells; 1994 Jul; 12(4):394-401. PubMed ID: 7951006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of residual leukemic cells in patients with acute promyelocytic leukemia by the fluorescence in situ hybridization method: potential for predicting relapse.
    Zhao L; Chang KS; Estey EH; Hayes K; Deisseroth AB; Liang JC
    Blood; 1995 Jan; 85(2):495-9. PubMed ID: 7812004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silence of the leukemic clone.
    Greaves M
    N Engl J Med; 1997 Jan; 336(5):367-9. PubMed ID: 9011792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.